Design, synthesis and biological profile of heterocyclic benzimidazole analogues as prospective antimicrobial and antiproliferative agents

Table 3 Antimicrobial screening results of synthesized derivatives

Comp.	Minimum inhibitory concentration (MIC = µM)
	Bacterial strains				Fungal strains
	SA MTCC3160	ST MTCC3231	KP MTCC9024	EC MTCC443	AN MTCC281	CA MTCC227
Z1	33.49	66.97	16.74	33.49	4.18	16.74
Z2	76.13	38.06	38.06	76.13	38.06	19.03
Z3	38.06	76.13	19.03	38.06	38.06	19.03
Z4	69.02	69.02	34.51	69.02	17.26	34.51
Z5	69.02	34.51	34.51	69.02	17.26	34.51
Z6	68.91	68.91	34.45	68.91	34.45	4.31
Z7	78.67	78.67	19.67	39.33	19.67	39.33
Z8	78.67	39.33	39.33	78.67	19.67	4.92
Z9	80.28	80.28	40.14	80.28	20.07	40.14
Z10	34.45	68.91	17.23	34.45	34.45	68.91
Z11	82.97	41.49	41.49	20.74	41.49	5.18
Z12	41.49	82.97	20.74	20.74	5.18	20.74
Z13	42.03	84.06	42.03	42.03	5.25	21.02
Z14	80.28	40.14	40.14	20.07	40.14	20.07
Z15	84.06	42.03	42.03	21.02	42.03	5.25
Z16	35.17	70.34	35.17	70.34	35.17	17.59
Z17	70.34	35.17	35.17	70.34	17.59	35.17
Z18	70.34	70.34	17.59	70.34	17.59	35.17
Z19	35.07	70.15	35.07	70.15	17.54	35.07
Z20	33.75	67.49	16.87	33.75	33.75	67.49
Z21	32.11	64.22	32.11	32.11	4.01	16.05
Z22	76.59	38.30	76.59	38.30	38.30	19.15
Z23	33.75	67.49	16.87	67.49	16.87	67.49
Z24	30.10	30.10	15.05	15.05	3.76	3.76
Z25	65.21	65.21	32.60	32.60	16.30	32.60
Z26	35.37	70.74	17.69	35.37	17.69	4.42
Z27	65.91	65.91	16.48	65.91	16.48	32.96
Z28	36.25	72.51	18.13	72.51	7.25	18.13
Z29	37.16	74.32	18.58	74.32	18.58	37.16
Z30	36.72	73.44	73.44	18.36	36.72	18.36
DMSO	NA	NA	NA	NA	NA	NA
Broth control	NG	NG	NG	NG	NG	NG
Std.	34.40^a	34.40^a	17.20^a	17.20^a	10.20^b	10.20^b

SA, Staphylococcus aureus; ST, Salmonella typhi; KP, Klebsiella pneumoniae; EC, Escherichia coli; CA, Candida albicans; AN, Aspergillus niger; DMSO, Dimethyl sulfoxide; NA, No activity; NG, No growth
Std drugs: ^aCefadroxil; ^bFluconazole

ISSN: 2661-801X